Recent News

IASLC 2021: Exploratory Analysis From IMpower010 Trial of Atezolizumab in Resectable NSCLC

ESMO 2021: Durvalumab-Based Combinations in COAST Trial of Locally Advanced NSCLC

IASLC 2021: CheckMate 907 on De Novo Administration of Nivolumab in Advanced NSCLC

FDA Approves Mobocertinib for NSCLC With EGFR Exon 20 Insertion Mutations

IASLC 2021: Antibody Response to SARS–CoV-2 Vaccination in Patients With Lung Cancer

IASLC 2021: POSEIDON Trial of Durvalumab Plus Tremelimumab in Metastatic NSCLC

Chemotherapy and Immunotherapy for KEAP1/NFE2L2-Mutant Lung Cancer

Autologous Tumor-Infiltrating Lymphocyte Treatment Under Study in Metastatic NSCLC

Amivantamb Under Study in Treatment of EGFR Exon 20 Insertion–Mutated NSCLC

Does Antibiotic Therapy Impact Outcomes to Chemoimmunotherapy in NSCLC?

TP53-Mutated Non–Small Cell Lung Cancer and Airborne Pollutants

Does the Use of Metformin Improve Outcomes in Patients With Non–Small Cell Lung Cancer?

IASLC Consensus Statement on Liquid Biopsy for Patients With Advanced NSCLC

Atezolizumab Receives Priority Review From the FDA in Early NSCLC

PET/CT Images: Measuring PD-L1 Status and Predicting Response to Immunotherapy in NSCLC

Can Postoperative Radiotherapy Improve Survival Outcomes in Patients With NSCLC?

Adding Durvalumab to Neoadjuvant Chemotherapy in Stage IIIA (N2) NSCLC

Can Adding Cetuximab to Afatinib Improve Outcomes in NSCLC?

Preliminary Results With Novel EGFR Inhibitor for EGFR-Mutated Lung Cancer

Updated Survival Outcomes From PACIFIC Trial of Immunotherapy for Stage III Lung Cancer

Breakthrough Therapy Designation Given to Adagrasib for KRAS G12C–Mutated NSCLC

Does Pembrolizumab Plus Chemotherapy–Induced Pneumonitis Impact Survival Outcomes in NSCLC?

ASCO 2021: LAG-3 Protein Plus Pembrolizumab Under Study in Metastatic Lung Cancer

ASCO 2021: EGFR- and MET-Based Biomarkers of Resistance to Therapy for Lung Cancer

AXL Inhibitor Bemcentinib Receives Fast Track Designation in Combination Therapy for Lung Cancer

Is KRAS Status Linked to Response to Immunotherapy for Advanced Lung Cancer?

ASCO 2021: 2-Year Follow-up With Nivolumab/Ipilimumab Plus Chemotherapy for Advanced Lung Cancer

Robotic Bronchoscopy May Improve Timing and Accuracy of Lung Cancer Diagnosis

ASCO 2021: Video-Assisted Thoracoscopy Versus Open Lobectomy for Early-Stage Lung Cancer

$20 Million Donation to MSK to Support Lung Cancer Research

ASCO 2021: Subgroup Efficacy Analysis of Sotorasib for Advanced KRAS G12C–Mutated NSCLC

ASCO 2021: Surgical Outcomes With Neoadjuvant Nivolumab Plus Chemotherapy in NSCLC

Anti–PD-1 Monoclonal Antibody Plus Chemotherapy for Advanced Squamous NSCLC

Sotorasib Receives Approval for NSCLC With KRAS G12C Mutations

FDA Accepts Submission for Sintilimab in Combination With Pemetrexed/Platinum Chemotherapy in NSCLC

Does Performance Status Correlate With Survival in Pembrolizumab-Treated Patients With NSCLC?

FDA Approves Targeted Therapy Amivantamab-vmjw for Subset of NSCLC

ASCO 2021: Atezolizumab in Early-Stage Resected NSCLC After Chemotherapy

RATIONALE 303 Update on Tislelizumab Versus Docetaxel in Advanced NSCLC

Priority Review Granted by FDA for Mobocertinib in Subtype of NSCLC

AACR 2021: Influence of Aneuploidy on Response to Immunotherapy for Lung Cancer

AACR 2021: Adding Nivolumab to Neoadjuvant Platinum-Doublet Chemotherapy for NSCLC

EGFR Inhibitor Mefatinib Under Study in Advanced EGFR-Mutant NSCLC